T23	che 4 12	tyrosine
T24	dis 51 75	chronic myeloid leukemia
T25	ggp 0 19	New tyrosine kinase
T1	Token 0 3	New
T2	Token 4 12	tyrosine
T3	Token 13 19	kinase
T4	Token 20 30	inhibitors
T5	Token 31 33	in
T6	Token 34 37	the
T7	Token 38 47	treatment
T8	Token 48 50	of
T9	Token 51 58	chronic
T10	Token 59 66	myeloid
T11	Token 67 75	leukemia
T12	Token 75 76	.
R1	amod Arg1:T4 Arg2:T1
R2	nn Arg1:T4 Arg2:T2
R3	nn Arg1:T4 Arg2:T3
R4	det Arg1:T7 Arg2:T6
R5	prep_in Arg1:T4 Arg2:T7
R6	amod Arg1:T11 Arg2:T9
R7	amod Arg1:T11 Arg2:T10
R8	prep_of Arg1:T7 Arg2:T11
R9	punct Arg1:T4 Arg2:T12
T93	che 77 94	Imatinib mesylate
T94	che 100 108	tyrosine
T95	che 289 294	Ph(+)
T96	dis 174 182	leukemia
T97	dis 191 215	chronic myeloid leukemia
T98	dis 217 220	CML
T99	dis 226 287	Philadelphia chromosome positive acute lymphoblastic leukemia
T100	dis 294 297	ALL
T101	ggp 96 115	Abl tyrosine kinase
T102	ggp 157 160	Bcr
T103	ggp 161 164	Abl
T26	Token 77 85	Imatinib
T27	Token 86 94	mesylate
T28	Token 94 95	,
T29	Token 96 99	Abl
T30	Token 100 108	tyrosine
T31	Token 109 115	kinase
T32	Token 116 125	inhibitor
T33	Token 125 126	,
T34	Token 127 130	has
T35	Token 131 139	improved
T36	Token 140 143	the
T37	Token 144 153	treatment
T38	Token 154 156	of
T39	Token 157 160	Bcr
T40	Token 160 161	-
T41	Token 161 164	Abl
T42	Token 164 165	-
T43	Token 165 173	positive
T44	Token 174 182	leukemia
T45	Token 183 187	such
T46	Token 188 190	as
T47	Token 191 198	chronic
T48	Token 199 206	myeloid
T49	Token 207 215	leukemia
T50	Token 216 217	(
T51	Token 217 220	CML
T52	Token 220 221	)
T53	Token 222 225	and
T54	Token 226 238	Philadelphia
T55	Token 239 249	chromosome
T56	Token 250 258	positive
T57	Token 259 264	acute
T58	Token 265 278	lymphoblastic
T59	Token 279 287	leukemia
T60	Token 288 289	(
T61	Token 289 291	Ph
T62	Token 291 292	(
T63	Token 292 293	+
T64	Token 293 294	)
T65	Token 294 297	ALL
T66	Token 297 298	)
T67	Token 298 299	.
R10	nn Arg1:T27 Arg2:T26
R11	nsubj Arg1:T35 Arg2:T27
R12	punct Arg1:T27 Arg2:T28
R13	nn Arg1:T32 Arg2:T29
R14	nn Arg1:T32 Arg2:T30
R15	nn Arg1:T32 Arg2:T31
R16	appos Arg1:T27 Arg2:T32
R17	punct Arg1:T27 Arg2:T33
R18	aux Arg1:T35 Arg2:T34
R19	det Arg1:T37 Arg2:T36
R20	dobj Arg1:T35 Arg2:T37
R21	amod Arg1:T44 Arg2:T43
R22	prep_of Arg1:T37 Arg2:T44
R23	amod Arg1:T49 Arg2:T47
R24	amod Arg1:T49 Arg2:T48
R25	prep_of Arg1:T37 Arg2:T49
R26	conj_such Arg1:T44 Arg2:T49
R27	punct Arg1:T51 Arg2:T50
R28	abbrev Arg1:T49 Arg2:T51
R29	punct Arg1:T51 Arg2:T52
R30	nn Arg1:T59 Arg2:T54
R31	nn Arg1:T59 Arg2:T55
R32	amod Arg1:T59 Arg2:T56
R33	amod Arg1:T59 Arg2:T57
R34	amod Arg1:T59 Arg2:T58
R35	conj_such Arg1:T44 Arg2:T59
R36	conj_and Arg1:T49 Arg2:T59
R37	punct Arg1:T65 Arg2:T60
R38	nn Arg1:T65 Arg2:T61
R39	punct Arg1:T61 Arg2:T62
R40	cc Arg1:T61 Arg2:T63
R41	punct Arg1:T61 Arg2:T64
R42	appos Arg1:T49 Arg2:T65
R43	punct Arg1:T65 Arg2:T66
R44	punct Arg1:T35 Arg2:T67
R45	hyphen Arg1:T41 Arg2:T39
R46	hyphen Arg1:T43 Arg2:T41
T129	dis 355 377	advanced-stage disease
T104	Token 300 307	However
T105	Token 307 308	,
T106	Token 309 319	resistance
T107	Token 320 322	is
T108	Token 323 328	often
T109	Token 329 337	reported
T110	Token 338 340	in
T111	Token 341 349	patients
T112	Token 350 354	with
T113	Token 355 369	advanced-stage
T114	Token 370 377	disease
T115	Token 377 378	.
R47	advmod Arg1:T109 Arg2:T104
R48	punct Arg1:T109 Arg2:T105
R49	nsubjpass Arg1:T109 Arg2:T106
R50	auxpass Arg1:T109 Arg2:T107
R51	advmod Arg1:T109 Arg2:T108
R52	prep_in Arg1:T109 Arg2:T111
R53	amod Arg1:T114 Arg2:T113
R54	prep_with Arg1:T111 Arg2:T114
R55	punct Arg1:T109 Arg2:T115
T192	che 393 401	tyrosine
T193	che 459 467	imatinib
T194	ggp 393 408	tyrosine kinase
T195	ggp 516 519	Bcr
T196	ggp 520 523	Abl
T197	ggp 555 572	Abl kinase domain
T130	Token 379 386	Several
T131	Token 387 392	novel
T132	Token 393 401	tyrosine
T133	Token 402 408	kinase
T134	Token 409 419	inhibitors
T135	Token 419 420	,
T136	Token 421 426	which
T137	Token 427 431	have
T138	Token 432 436	been
T139	Token 437 446	developed
T140	Token 447 449	to
T141	Token 450 458	override
T142	Token 459 467	imatinib
T143	Token 468 478	resistance
T144	Token 479 489	mechanisms
T145	Token 490 494	such
T146	Token 495 497	as
T147	Token 498 512	overexpression
T148	Token 513 515	of
T149	Token 516 519	Bcr
T150	Token 519 520	-
T151	Token 520 523	Abl
T152	Token 524 527	and
T153	Token 528 533	point
T154	Token 534 543	mutations
T155	Token 544 550	within
T156	Token 551 554	the
T157	Token 555 558	Abl
T158	Token 559 565	kinase
T159	Token 566 572	domain
T160	Token 572 573	,
T161	Token 574 577	are
T162	Token 578 587	currently
T163	Token 588 597	competing
T164	Token 597 598	.
R56	amod Arg1:T134 Arg2:T130
R57	amod Arg1:T134 Arg2:T131
R58	nn Arg1:T134 Arg2:T132
R59	nn Arg1:T134 Arg2:T133
R60	nsubjpass Arg1:T139 Arg2:T134
R61	nsubj Arg1:T163 Arg2:T134
R62	punct Arg1:T134 Arg2:T135
R63	aux Arg1:T139 Arg2:T137
R64	auxpass Arg1:T139 Arg2:T138
R65	rcmod Arg1:T134 Arg2:T139
R66	aux Arg1:T141 Arg2:T140
R67	xcomp Arg1:T139 Arg2:T141
R68	nn Arg1:T144 Arg2:T142
R69	nn Arg1:T144 Arg2:T143
R70	dobj Arg1:T141 Arg2:T144
R71	prep_such_as Arg1:T144 Arg2:T147
R72	nn Arg1:T154 Arg2:T151
R73	conj_and Arg1:T151 Arg2:T153
R74	nn Arg1:T154 Arg2:T153
R75	prep_of Arg1:T147 Arg2:T154
R76	det Arg1:T159 Arg2:T156
R77	nn Arg1:T159 Arg2:T157
R78	nn Arg1:T159 Arg2:T158
R79	prep_within Arg1:T154 Arg2:T159
R80	punct Arg1:T134 Arg2:T160
R81	aux Arg1:T163 Arg2:T161
R82	advmod Arg1:T163 Arg2:T162
R83	punct Arg1:T163 Arg2:T164
R84	hyphen Arg1:T151 Arg2:T149
T237	che 617 625	tyrosine
T238	che 675 678	ATP
T239	che 695 698	ATP
T240	ggp 613 632	Abl tyrosine kinase
T198	Token 599 609	Inhibitors
T199	Token 610 612	of
T200	Token 613 616	Abl
T201	Token 617 625	tyrosine
T202	Token 626 632	kinase
T203	Token 633 636	are
T204	Token 637 644	divided
T205	Token 645 649	into
T206	Token 650 653	two
T207	Token 654 658	main
T208	Token 659 665	groups
T209	Token 665 666	,
T210	Token 667 673	namely
T211	Token 673 674	,
T212	Token 675 678	ATP
T213	Token 678 679	-
T214	Token 679 690	competitive
T215	Token 691 694	and
T216	Token 695 698	ATP
T217	Token 699 714	non-competitive
T218	Token 715 725	inhibitors
T219	Token 725 726	.
R85	nsubjpass Arg1:T204 Arg2:T198
R86	nn Arg1:T202 Arg2:T200
R87	nn Arg1:T202 Arg2:T201
R88	prep_of Arg1:T198 Arg2:T202
R89	auxpass Arg1:T204 Arg2:T203
R90	num Arg1:T208 Arg2:T206
R91	amod Arg1:T208 Arg2:T207
R92	prep_into Arg1:T204 Arg2:T208
R93	punct Arg1:T208 Arg2:T209
R94	advmod Arg1:T208 Arg2:T210
R95	punct Arg1:T208 Arg2:T211
R96	amod Arg1:T218 Arg2:T214
R97	dep Arg1:T217 Arg2:T216
R98	conj_and Arg1:T214 Arg2:T217
R99	amod Arg1:T218 Arg2:T217
R100	appos Arg1:T208 Arg2:T218
R101	punct Arg1:T204 Arg2:T219
R102	hyphen Arg1:T214 Arg2:T212
T280	che 737 740	ATP
T281	che 827 849	2-phenylaminopyrimidin
T282	ggp 803 806	Src
T283	ggp 807 810	Abl
T241	Token 727 735	Moreover
T242	Token 735 736	,
T243	Token 737 740	ATP
T244	Token 740 741	-
T245	Token 741 752	competitive
T246	Token 753 763	inhibitors
T247	Token 764 767	are
T248	Token 768 772	fall
T249	Token 773 777	into
T250	Token 778 781	two
T251	Token 782 792	subclasses
T252	Token 792 793	,
T253	Token 794 798	i.e.
T254	Token 799 802	the
T255	Token 803 806	Src
T256	Token 806 807	/
T257	Token 807 810	Abl
T258	Token 811 821	inhibitors
T259	Token 821 822	,
T260	Token 823 826	and
T261	Token 827 849	2-phenylaminopyrimidin
T262	Token 849 850	-
T263	Token 850 855	based
T264	Token 856 865	compounds
T265	Token 865 866	.
R103	advmod Arg1:T248 Arg2:T241
R104	punct Arg1:T248 Arg2:T242
R105	amod Arg1:T246 Arg2:T245
R106	nsubj Arg1:T248 Arg2:T246
R107	aux Arg1:T248 Arg2:T247
R108	num Arg1:T251 Arg2:T250
R109	prep_into Arg1:T248 Arg2:T251
R110	punct Arg1:T251 Arg2:T252
R111	prep Arg1:T251 Arg2:T253
R112	det Arg1:T258 Arg2:T254
R113	nn Arg1:T258 Arg2:T255
R114	pobj Arg1:T253 Arg2:T258
R115	punct Arg1:T251 Arg2:T259
R116	amod Arg1:T264 Arg2:T263
R117	prep_into Arg1:T248 Arg2:T264
R118	conj_and Arg1:T251 Arg2:T264
R119	punct Arg1:T248 Arg2:T265
R120	hyphen Arg1:T245 Arg2:T243
R121	slash Arg1:T255 Arg2:T257
R122	hyphen Arg1:T263 Arg2:T261
T346	che 867 876	Dasatinib
T347	che 887 897	BMS-354825
T348	che 900 907	AP23464
T349	che 909 916	SKI-606
T350	che 921 929	PD166326
T351	che 973 979	AMN107
T352	che 984 990	NS-187
T353	che 992 1000	INNO-406
T354	ggp 900 907	AP23464
T355	ggp 909 916	SKI-606
T356	ggp 921 929	PD166326
T357	ggp 948 951	Src
T358	ggp 952 955	Abl
T359	ggp 973 979	AMN107
T284	Token 867 876	Dasatinib
T285	Token 877 878	(
T286	Token 878 886	formerly
T287	Token 887 897	BMS-354825
T288	Token 897 898	)
T289	Token 898 899	,
T290	Token 900 907	AP23464
T291	Token 907 908	,
T292	Token 909 916	SKI-606
T293	Token 917 920	and
T294	Token 921 929	PD166326
T295	Token 930 933	are
T296	Token 934 944	classified
T297	Token 945 947	as
T298	Token 948 951	Src
T299	Token 951 952	/
T300	Token 952 955	Abl
T301	Token 956 966	inhibitors
T302	Token 967 972	while
T303	Token 973 979	AMN107
T304	Token 980 983	and
T305	Token 984 990	NS-187
T306	Token 991 992	(
T307	Token 992 1000	INNO-406
T308	Token 1000 1001	)
T309	Token 1002 1008	belong
T310	Token 1009 1011	to
T311	Token 1012 1015	the
T312	Token 1016 1022	latter
T313	Token 1023 1031	subclass
T314	Token 1032 1034	of
T315	Token 1035 1045	inhibitors
T316	Token 1045 1046	.
R123	nsubjpass Arg1:T296 Arg2:T284
R124	punct Arg1:T287 Arg2:T285
R125	advmod Arg1:T287 Arg2:T286
R126	appos Arg1:T284 Arg2:T287
R127	punct Arg1:T287 Arg2:T288
R128	punct Arg1:T284 Arg2:T289
R129	conj_and Arg1:T284 Arg2:T290
R130	nsubjpass Arg1:T296 Arg2:T290
R131	punct Arg1:T284 Arg2:T291
R132	conj_and Arg1:T284 Arg2:T292
R133	nsubjpass Arg1:T296 Arg2:T292
R134	conj_and Arg1:T284 Arg2:T294
R135	nsubjpass Arg1:T296 Arg2:T294
R136	auxpass Arg1:T296 Arg2:T295
R137	nn Arg1:T301 Arg2:T298
R138	prep_as Arg1:T296 Arg2:T301
R139	mark Arg1:T309 Arg2:T302
R140	nsubj Arg1:T309 Arg2:T303
R141	conj_and Arg1:T303 Arg2:T305
R142	nsubj Arg1:T309 Arg2:T305
R143	punct Arg1:T307 Arg2:T306
R144	appos Arg1:T303 Arg2:T307
R145	punct Arg1:T307 Arg2:T308
R146	advcl Arg1:T296 Arg2:T309
R147	det Arg1:T313 Arg2:T311
R148	amod Arg1:T313 Arg2:T312
R149	prep_to Arg1:T309 Arg2:T313
R150	prep_of Arg1:T313 Arg2:T315
R151	punct Arg1:T296 Arg2:T316
R152	slash Arg1:T298 Arg2:T300
T403	che 1087 1096	dasatinib
T404	che 1101 1107	AMN107
T360	Token 1047 1052	Among
T361	Token 1053 1058	these
T362	Token 1059 1065	agents
T363	Token 1065 1066	,
T364	Token 1067 1075	clinical
T365	Token 1076 1083	studies
T366	Token 1084 1086	on
T367	Token 1087 1096	dasatinib
T368	Token 1097 1100	and
T369	Token 1101 1107	AMN107
T370	Token 1108 1111	had
T371	Token 1112 1119	started
T372	Token 1120 1127	earlier
T373	Token 1128 1132	than
T374	Token 1133 1136	the
T375	Token 1137 1143	others
T376	Token 1144 1147	and
T377	Token 1148 1157	favorable
T378	Token 1158 1165	results
T379	Token 1166 1169	are
T380	Token 1170 1182	accumulating
T381	Token 1182 1183	.
R153	det Arg1:T362 Arg2:T361
R154	prep_among Arg1:T371 Arg2:T362
R155	punct Arg1:T371 Arg2:T363
R156	amod Arg1:T365 Arg2:T364
R157	nsubj Arg1:T371 Arg2:T365
R158	prep_on Arg1:T365 Arg2:T367
R159	prep_on Arg1:T365 Arg2:T369
R160	conj_and Arg1:T367 Arg2:T369
R161	aux Arg1:T371 Arg2:T370
R162	advmod Arg1:T371 Arg2:T372
R163	mark Arg1:T380 Arg2:T373
R164	det Arg1:T375 Arg2:T374
R165	nsubj Arg1:T380 Arg2:T375
R166	amod Arg1:T378 Arg2:T377
R167	conj_and Arg1:T375 Arg2:T378
R168	nsubj Arg1:T380 Arg2:T378
R169	aux Arg1:T380 Arg2:T379
R170	dep Arg1:T372 Arg2:T380
R171	punct Arg1:T371 Arg2:T381
T440	che 1230 1236	NS-187
T441	che 1238 1246	INNO-406
T405	Token 1184 1192	Clinical
T406	Token 1193 1200	studies
T407	Token 1201 1203	of
T408	Token 1204 1209	other
T409	Token 1210 1219	compounds
T410	Token 1220 1229	including
T411	Token 1230 1236	NS-187
T412	Token 1237 1238	(
T413	Token 1238 1246	INNO-406
T414	Token 1246 1247	)
T415	Token 1248 1252	will
T416	Token 1253 1255	be
T417	Token 1256 1265	performed
T418	Token 1266 1268	in
T419	Token 1269 1274	rapid
T420	Token 1275 1285	succession
T421	Token 1285 1286	.
R172	amod Arg1:T406 Arg2:T405
R173	nsubjpass Arg1:T417 Arg2:T406
R174	amod Arg1:T409 Arg2:T408
R175	prep_of Arg1:T406 Arg2:T409
R176	prep_including Arg1:T409 Arg2:T411
R177	punct Arg1:T413 Arg2:T412
R178	abbrev Arg1:T411 Arg2:T413
R179	punct Arg1:T413 Arg2:T414
R180	aux Arg1:T417 Arg2:T415
R181	auxpass Arg1:T417 Arg2:T416
R182	amod Arg1:T420 Arg2:T419
R183	prep_in Arg1:T417 Arg2:T420
R184	punct Arg1:T417 Arg2:T421
T473	che 1324 1327	ATP
T474	che 1376 1384	imatinib
T442	Token 1287 1294	Because
T443	Token 1295 1297	of
T444	Token 1298 1301	its
T445	Token 1302 1308	strong
T446	Token 1309 1317	affinity
T447	Token 1317 1318	,
T448	Token 1319 1323	most
T449	Token 1324 1327	ATP
T450	Token 1328 1339	competitive
T451	Token 1340 1350	inhibitors
T452	Token 1351 1354	may
T453	Token 1355 1357	be
T454	Token 1358 1367	effective
T455	Token 1368 1375	against
T456	Token 1376 1384	imatinib
T457	Token 1384 1385	-
T458	Token 1385 1394	resistant
T459	Token 1395 1403	patients
T460	Token 1403 1404	.
R185	prepc_because_of Arg1:T454 Arg2:T443
R186	poss Arg1:T446 Arg2:T444
R187	amod Arg1:T446 Arg2:T445
R188	pobj Arg1:T454 Arg2:T446
R189	punct Arg1:T454 Arg2:T447
R190	amod Arg1:T451 Arg2:T448
R191	nn Arg1:T451 Arg2:T449
R192	amod Arg1:T451 Arg2:T450
R193	nsubj Arg1:T454 Arg2:T451
R194	aux Arg1:T454 Arg2:T452
R195	cop Arg1:T454 Arg2:T453
R196	amod Arg1:T459 Arg2:T458
R197	prep_against Arg1:T454 Arg2:T459
R198	punct Arg1:T454 Arg2:T460
R199	hyphen Arg1:T458 Arg2:T456
T520	che 1426 1429	ATP
T521	ggp 1492 1505	T315I Bcr-Abl
T475	Token 1405 1412	However
T476	Token 1412 1413	,
T477	Token 1414 1416	to
T478	Token 1417 1421	date
T479	Token 1421 1422	,
T480	Token 1423 1425	an
T481	Token 1426 1429	ATP
T482	Token 1429 1430	-
T483	Token 1430 1441	competitive
T484	Token 1442 1451	inhibitor
T485	Token 1452 1456	that
T486	Token 1457 1460	can
T487	Token 1461 1468	inhibit
T488	Token 1469 1472	the
T489	Token 1473 1488	phosphorylation
T490	Token 1489 1491	of
T491	Token 1492 1497	T315I
T492	Token 1498 1505	Bcr-Abl
T493	Token 1506 1509	has
T494	Token 1510 1513	not
T495	Token 1514 1517	yet
T496	Token 1518 1522	been
T497	Token 1523 1532	developed
T498	Token 1532 1533	.
R200	advmod Arg1:T497 Arg2:T475
R201	punct Arg1:T497 Arg2:T476
R202	prep_to Arg1:T497 Arg2:T478
R203	punct Arg1:T497 Arg2:T479
R204	det Arg1:T484 Arg2:T480
R205	amod Arg1:T484 Arg2:T483
R206	nsubj Arg1:T487 Arg2:T484
R207	nsubjpass Arg1:T497 Arg2:T484
R208	aux Arg1:T487 Arg2:T486
R209	rcmod Arg1:T484 Arg2:T487
R210	det Arg1:T489 Arg2:T488
R211	dobj Arg1:T487 Arg2:T489
R212	nn Arg1:T492 Arg2:T491
R213	prep_of Arg1:T489 Arg2:T492
R214	aux Arg1:T497 Arg2:T493
R215	neg Arg1:T497 Arg2:T494
R216	advmod Arg1:T497 Arg2:T495
R217	auxpass Arg1:T497 Arg2:T496
R218	punct Arg1:T497 Arg2:T498
R219	hyphen Arg1:T483 Arg2:T481
T567	che 1559 1562	ATP
T568	che 1598 1606	ON012380
T569	che 1632 1638	VX-680
T570	ggp 1608 1621	Aurora kinase
T571	ggp 1643 1657	p38 MAP kinase
T522	Token 1534 1536	To
T523	Token 1537 1544	address
T524	Token 1545 1549	this
T525	Token 1550 1557	problem
T526	Token 1557 1558	,
T527	Token 1559 1562	ATP
T528	Token 1563 1578	non-competitive
T529	Token 1579 1589	inhibitors
T530	Token 1590 1594	such
T531	Token 1595 1597	as
T532	Token 1598 1606	ON012380
T533	Token 1606 1607	,
T534	Token 1608 1614	Aurora
T535	Token 1615 1621	kinase
T536	Token 1622 1631	inhibitor
T537	Token 1632 1638	VX-680
T538	Token 1639 1642	and
T539	Token 1643 1646	p38
T540	Token 1647 1650	MAP
T541	Token 1651 1657	kinase
T542	Token 1658 1667	inhibitor
T543	Token 1668 1676	BIRB-796
T544	Token 1677 1681	have
T545	Token 1682 1686	been
T546	Token 1687 1696	developed
T547	Token 1696 1697	.
R220	aux Arg1:T523 Arg2:T522
R221	det Arg1:T525 Arg2:T524
R222	dobj Arg1:T523 Arg2:T525
R223	punct Arg1:T523 Arg2:T526
R224	nn Arg1:T529 Arg2:T527
R225	amod Arg1:T529 Arg2:T528
R226	nsubjpass Arg1:T546 Arg2:T529
R227	prep_such_as Arg1:T529 Arg2:T532
R228	punct Arg1:T532 Arg2:T533
R229	nn Arg1:T536 Arg2:T534
R230	nn Arg1:T536 Arg2:T535
R231	appos Arg1:T532 Arg2:T536
R232	num Arg1:T536 Arg2:T537
R233	nn Arg1:T542 Arg2:T539
R234	nn Arg1:T542 Arg2:T540
R235	nn Arg1:T542 Arg2:T541
R236	appos Arg1:T532 Arg2:T542
R237	conj_and Arg1:T536 Arg2:T542
R238	num Arg1:T542 Arg2:T543
R239	aux Arg1:T546 Arg2:T544
R240	auxpass Arg1:T546 Arg2:T545
R241	dep Arg1:T523 Arg2:T546
R242	punct Arg1:T523 Arg2:T547
T635	che 1749 1754	Ph(+)
T636	che 1837 1840	ATP
T637	dis 1741 1744	CML
T572	Token 1698 1700	It
T573	Token 1701 1704	may
T574	Token 1705 1707	be
T575	Token 1708 1717	necessary
T576	Token 1718 1721	for
T577	Token 1722 1725	the
T578	Token 1726 1737	improvement
T579	Token 1738 1740	of
T580	Token 1741 1744	CML
T581	Token 1745 1748	and
T582	Token 1749 1751	Ph
T583	Token 1751 1752	(
T584	Token 1752 1753	+
T585	Token 1753 1754	)
T586	Token 1754 1757	ALL
T587	Token 1758 1767	treatment
T588	Token 1768 1770	to
T589	Token 1771 1773	be
T590	Token 1774 1779	taken
T591	Token 1780 1784	into
T592	Token 1785 1798	consideration
T593	Token 1799 1801	of
T594	Token 1802 1805	the
T595	Token 1806 1817	combination
T596	Token 1818 1825	therapy
T597	Token 1826 1830	with
T598	Token 1831 1836	novel
T599	Token 1837 1840	ATP
T600	Token 1840 1841	-
T601	Token 1841 1852	competitive
T602	Token 1853 1863	inhibitors
T603	Token 1864 1867	and
T604	Token 1868 1873	these
T605	Token 1874 1880	agents
T606	Token 1880 1881	.
R243	nsubj Arg1:T575 Arg2:T572
R244	aux Arg1:T575 Arg2:T573
R245	cop Arg1:T575 Arg2:T574
R246	det Arg1:T578 Arg2:T577
R247	prep_for Arg1:T575 Arg2:T578
R248	prep_of Arg1:T578 Arg2:T580
R249	prep_of Arg1:T578 Arg2:T582
R250	conj_and Arg1:T580 Arg2:T582
R251	punct Arg1:T582 Arg2:T583
R252	cc Arg1:T582 Arg2:T584
R253	punct Arg1:T582 Arg2:T585
R254	det Arg1:T587 Arg2:T586
R255	nsubjpass Arg1:T590 Arg2:T587
R256	aux Arg1:T590 Arg2:T588
R257	auxpass Arg1:T590 Arg2:T589
R258	xcomp Arg1:T575 Arg2:T590
R259	prep_into Arg1:T590 Arg2:T592
R260	det Arg1:T596 Arg2:T594
R261	nn Arg1:T596 Arg2:T595
R262	prep_of Arg1:T592 Arg2:T596
R263	amod Arg1:T602 Arg2:T598
R264	amod Arg1:T602 Arg2:T601
R265	prep_with Arg1:T590 Arg2:T602
R266	det Arg1:T605 Arg2:T604
R267	prep_with Arg1:T590 Arg2:T605
R268	conj_and Arg1:T602 Arg2:T605
R269	punct Arg1:T575 Arg2:T606
R270	hyphen Arg1:T601 Arg2:T599
